Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 1 of the last 1 fiscal years.
-
Tight liquidity NBB
Cash and receivables cover 3 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
ASG Pharma Invest from Ieper, company number BE1012783235, closed financial year 2025 with a result of € -33,784 after tax. For that financial year ASG Pharma Invest recorded a gross margin of € 75,301 and equity of € -13,784. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on March 11, 2026.
€ -13,784
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -33,784
Profit after tax over the fiscal year.
€ 12,109
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -33,784.
Debts at end 2025
€ 2 million
€ 138,500 is repaid this year. At this pace the long-term loan is gone in ≈ 15 years.
€ 4,027
Supplier invoices still open on the last day of the fiscal year.
€ 4,338
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
What happened to ASG Pharma Invest?
What happened at ASG Pharma Invest in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 33,784. Source: NBB ↗
- New establishment in Ieper. KBO
- Start of the company according to the CBE. KBO
A new publication or filing at ASG Pharma Invest? We notify you, reason included.
Follow ASG Pharma InvestDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind ASG Pharma Invest are Anse SAINT-GERMAIN and Jonas DEGROOTE. It owns 100% of Apotheek Saint-Germain itself.
Directors
According to the 2025 annual accounts
Establishments
Establishment units
Physical locations of this company
Komenseweg 18
8900 Ieper
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 1012.783.235
- VAT number
- BE 1012.783.235
- Registered office
- Komenseweg 18, 8900 Ieper
- Names & denominations
- ASG Pharma Invest
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 26 August 2024
- Peppol
- Active · Active since 5 Oct 2025
- Activities · NACE
Activiteiten van hoofdkantoren
Verhuur en exploitatie van eigen of geleased residentieel onroerend goed, exclusief sociale woningen